Pharma Foods International Co., Ltd.

2929

JP3802310007

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
844 ^JPY	+1.81%		+4.46%	-15.77%

Mar. 15	Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending July 31, 2024	CI
Mar. 15	Pharma Foods International Co., Ltd. Announces Dividend for the Second Quarter of the Fiscal Year Ending July 31, 2024, Payable on April 2, 2024	CI

Pharma Foods International Co., Ltd. authorizes a Buyback Plan.

January 04, 2024

The Board of Directors of Pharma Foods International Co., Ltd. has authorized a buyback plan on January 5, 2024.

Latest news about Pharma Foods International Co., Ltd.

Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending July 31, 2024	Mar. 15	CI
Pharma Foods International Co., Ltd. Announces Dividend for the Second Quarter of the Fiscal Year Ending July 31, 2024, Payable on April 2, 2024	Mar. 15	CI
Tranche Update on Pharma Foods International Co., Ltd.'s Equity Buyback Plan announced on January 5, 2024.	Jan. 22	CI
Pharma Foods International Co., Ltd.'s Equity Buyback announced on January 5, 2024, has closed with 874,100 shares, representing 3.03% for ¥999.9 million.	Jan. 18	CI
Pharma Foods International Co., Ltd. announces an Equity Buyback for 1,100,000 shares, representing 3.8% for ¥1,000 million.	Jan. 05	CI
Pharma Foods International Co., Ltd. authorizes a Buyback Plan.	Jan. 04	CI
Pharma Foods International Return to the Black in Fiscal Q1	Dec. 12	MT
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending July 31, 2024	Dec. 12	CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Year Ending July 31, 2024	Dec. 12	CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2024	Dec. 12	CI
Pharma Foods International Co., Ltd. agreed to acquire Healthcare Mail Order Business Of Daicel from Daicel Corporation.	23-09-19	CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2024	23-09-10	CI
Pharma Foods International Co., Ltd. Reports Dividend Result for the Second Quarter Ending July 31, 2023; Provides Dividend Guidance for the Second Quarter Ending July 31, 2024	23-09-10	CI
Pharma Foods International Co., Ltd. Reports Dividend Result for year Ending July 31, 2023, Payable on October 26, 2023	23-09-10	CI
Pharma Foods International Co., Ltd. Expects Dividend for the Year Ending July 31, 2024	23-09-10	CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Year Ending July 31, 2023	23-06-06	CI
Pharma Foods International Co., Ltd. Reports Earnings Results for the Nine Months Ended April 30, 2023	23-06-04	CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2023	23-06-04	CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending July 31, 2023	23-03-08	CI
Pharma Foods International Co., Ltd. completed the acquisition of the Bioscience Business of Integrale Co Ltd. for ¥140 million.	22-12-11	CI
Pharma Foods International Turns to Fiscal Q1 Loss on Higher Expenses	22-12-08	MT
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending July 31, 2023	22-12-06	CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending July 31, 2023	22-12-06	CI
Tranche Update on Pharma Foods International Co., Ltd.'s Equity Buyback Plan announced on October 7, 2022.	22-10-25	CI
Pharma Foods International Co., Ltd.'s Equity Buyback announced on October 7, 2022, has closed with 242,200 shares, representing 0.83% for ¥299.98 million.	22-10-23	CI

Chart Pharma Foods International Co., Ltd.

Duration

Period

Chart Pharma Foods International Co., Ltd.

More charts

Pharma Foods International Co., Ltd. is a Japan-based company mainly engaged in mail order business and functional materials business. The Company operates through three business segments. The Mail Order segment is engaged in the sale of supplement Tamagosamin, cosmetics Pearl Skin Lanchel and Derma QII Mild Peeling Gel, through advertising media such as televisions and radios. The Functional Materials segment is engaged in the development and sale of functional materials such as GABA, Bonepep, Folic Acid eggs and Chicken Egg Antibody. The Company is also engaged in the planning and sale of original equipment manufacturer (OEM) products such as supplements and beverages. The Biomedical segment is engaged in the antibody contract manufacture business for drug discovery and diagnostics, and life science information (LSI) business for analysis and efficacy evaluation test of materials and products.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMA FOODS INTERNATIONAL CO., LTD.	-15.77%	151M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research